Equine viral arteritis is an infrequently encountered contagious viral disease of equids that has assumed increased veterinary medical and economic significance since the 1984 epidemic in Thoroughbreds in Kentucky. The most important consequences of this infection are abortion in the mare and establishment of the carrier state in the stallion. Equine arteritis virus becomes localized in the reproductive tract of a relatively high percentage of infected stallions which serve as very efficient transmitters of the infection through direct or indirect venereal contact with susceptible mares. The long-term persistently infected stallion appears to play a major epidemiologic role in the dissemination and perpetuation of the virus in horse populations throughout the world. Aspects of the pathogenesis, immunity, and epidemiology of equine arteritis virus are discussed in relation to current methods for the diagnosis, treatment, and control of this disease.

The N-terminal hydrophilic ectodomain of the G(L) envelope glycoprotein of equine arteritis virus (EAV) contains neutralization determinants of the virus. We developed a panel of 17 neutralizing murine monoclonal antibodies (MAbs) to further characterize the neutralization determinants of EAV. Included were 6 MAbs previously raised against a laboratory strain (EAVUCD) of the original Bucyrus strain of EAV, as well as 11 additional MAbs that were raised against a neutralization-resistant variant [escape mutant (EM)] virus (EM6D10) that was derived from EAVUCD. All MAbs raised against EAVUCD and 4 of the MAbs raised against EM6D10 (2B3, 5F8, 8D4, and 10B4) reacted with the corresponding G(L) envelope glycoprotein in a Western immunoblotting assay, whereas the remaining 7 MAbs raised against EM6D10 did not react with any viral protein in the immunoblotting assay but competitively inhibited the binding of MAbs 2B3, 5F8, 8D4, and 10B4, indicating that they also recognize epitopes on the G(L) protein. A panel of 18 EM viruses raised to the MAb panel, 19 field isolates of EAV from North America and Europe, the modified-live virus vaccine (ARVAC), and 3 other laboratory strains of EAV were characterized by microneutralization assay with the panel of neutralizing MAbs and polyclonal rabbit and horse antisera. Comparative analysis of the nucleotide sequences of ORF5 and the deduced amino acid sequences of the G(L) protein of individual EM viruses and field isolates of EAV identified four distinct neutralization sites. These sites include amino acids 49 (site A), 61 (site B), 67 through 90 (site C), and 99 through 106 (site D). With the notable exception of site A, the sites were all located in the V1 variable region (amino acids 61-121) within the second half of the N-terminal hydrophilic ectodomain of the G(L) protein. Site D includes several overlapping linear epitopes which appear to interact with amino acids in the other three sites to form conformationally dependent epitopes. Amino acid substitutions within any of these four sites can alter the neutralization phenotype of individual strains of EAV.

No abstract

The variation and phylogenetic relationship of open reading frame 5 (ORF5) of 3 different laboratory strains of the original prototype Bucyrus strain of equine arteritis virus (EAV), the modified live virus vaccine (ARVAC, Fort Dodge Laboratories), and 18 field isolates of EAV from North America and Europe were determined by comparison of their gene sequences. The viruses differed from the published sequence by between 3 (99.6% homology) and 94 (87.8%) nucleotides and by between 3 (98.8%) and 24 (90.6%) amino acids. The field isolates differed from each other by between 2 (99.7%) and 110 (85.7%) nucleotides and by between 1 (99.6%) and 26 (89.8%) amino acids. Comparison of the nucleotide sequences of these viruses indicates that although they are very closely related, the ORF5 of each virus is distinct. The ORF5 of EAV encodes the GL envelope glycoprotein which expresses the neutralization determinants of the virus. Comparative analysis of the deduced amino acid sequence of the GL protein of the viruses identified three distinct variable regions (V1 [aa 61-121], V2 [141-178], and V3 [aa 202-222]), a putative signal sequence (S [aa 1-18]), and four conserved regions (C1 [aa 19-60], C2 [aa 122-140], C3 [aa 179-201], and C4 [aa 223-255]). Amino acid substitutions in the V1 region of the GL protein of EAV field isolates had significant effects on the predicted hydrophobicity and secondary structure of the protein, which is potentially important because this region contains a major neutralization site. Estimation of genetic distances and phylogenetic tree analysis of these viruses identified four distinct groups of EAV isolates, including two North American (NA1 and NA2) and two European (E1 and E2) groups. The sequence data obtained from individual European and North American isolates suggest movement of viruses between the two continents.

The complete genome sequence of the first equine coronavirus (ECoV) isolate, NC99 strain was accomplished by directly sequencing 11 overlapping fragments which were RT-PCR amplified from viral RNA. The ECoV genome is 30,992 nucleotides in length, excluding the polyA tail. Analysis of the sequence identified 11 open reading frames which encode two replicase polyproteins, five structural proteins (hemagglutinin esterase, spike, envelope, membrane, and nucleocapsid) and four accessory proteins (NS2, p4.7, p12.7, and I). The two replicase polyproteins are predicted to be proteolytically processed by three virus-encoded proteases into 16 non-structural proteins (nsp1-16). The ECoV nsp3 protein had considerable amino acid deletions and insertions compared to the nsp3 proteins of bovine coronavirus, human coronavirus OC43, and porcine hemagglutinating encephalomyelitis virus, three group 2 coronaviruses phylogenetically most closely related to ECoV. The structure of subgenomic mRNAs was analyzed by Northern blot analysis and sequencing of the leader-body junction in each sg mRNA.

A panel of archived EHV-1 isolates collected (1951 to 2006) from equine abortions was analyzed using a real-time Taq-Man ® allelic discrimination PCR. Based on previous findings, isolates possessing adenine at nucleotide position 2254 (A 2254) in ORF30 were classified as having a non-neuropathogenic genotype and those with guanine at 2254 (G 2254) were designated as the neuropathogenic genotype. The resultant data demonstrated that viruses with the neuropathogenic genotype existed in the 1950s and isolates with this genotype increased from 3.3% in the 1960s to 14.4% in the 1990s. The incidence of EHV-1 isolates from 2000 to 2006 with G at position 2254 is 19.4%, suggesting that viruses with the neuropathogenic genotype are continuing to increase in prevalence within the latent reservoir of the virus, leading to greater risks for costly outbreaks of equine herpesvirus neurologic disease. Another highly significant finding was two isolates failed to react with either probe in the allelic discrimination assay. These isolates were found to possess an adenine to cytosine substitution at position 2258 (A 2258 →C 2258) in ORF30, in addition to A 2254 →G 2254. Interestingly, the nonneuropathogenic RAC-H modified live vaccine strain of EHV-1 also contains both A 2254 →G 2254 and A 2258 →C 2258 substitutions. This finding clearly suggests that additional research is required before the genetic basis of the neuropathogenic phenotype in EHV-1 is fully understood.

A highly contagious virus infection of horses, influenza is the single most important equine respiratory disease in many countries. Two subtypes of equine influenza virus have been identified, A/equine-1 and A/equine-2, neither of which immunologically cross-reacts. In the case of A/equine-2 virus, two lineages exist, American and European, which appear to have evolved independently of one another. The acute febrile respiratory disease characteristic of influenza is frequently complicated by secondary bacterial infection, especially in unvaccinated horses. Primarily a respiratory-borne infection, influenza has been spread to a significant number of countries through the international movement of horses. Strains of A/equine-2 virus have been responsible for all known outbreaks of the disease since 1980. Simple rapid procedures are now available for the diagnosis of equine influenza. Prevention and control of influenza is based on frequent use of inactivated, adjuvanted vaccines, which confer only incomplete and short-term protection against this disease. To be maximally effective, vaccines need to be periodically updated and include influenza virus strains closely related to those in current circulation.

No abstract